To which class of antidiabetic drugs does acarbose belong?
Acarbose is generally classified as an alpha-glucosidase inhibitor—a class of antidiabetic medications.
Under normal physiological conditions, staple foods consumed by humans contain substantial amounts of starch, a polysaccharide. However, the form of glucose that the human body can directly utilize is monosaccharide. The conversion of polysaccharides into monosaccharides occurs gradually via the action of glycosidases—enzymes primarily located in the intestinal tract. Upon ingestion, starch is progressively broken down into glucose by these enzymes and subsequently absorbed for energy production. Acarbose exerts its therapeutic effect primarily by inhibiting the activity of these glycosidases, thereby reducing the breakdown of dietary carbohydrates (e.g., starch) from polysaccharides into absorbable monosaccharides. As a result, glucose absorption is delayed and diminished, helping to mitigate postprandial hyperglycemia.
Acarbose is an antidiabetic agent commonly used clinically in conjunction with dietary management for the treatment of diabetes mellitus. It is also effective in lowering postprandial blood glucose levels in patients with impaired glucose tolerance. However, its use may cause gastrointestinal side effects, including flatulence and increased bowel sounds (borborygmi).